Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Leiolizumab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : BVF Partners
Deal Size : $225.0 million
Deal Type : Series B Financing
AltruBio Secures $225m for Immune Checkpoint Programme Development
Details : The proceeds will advance the clinical development of the Company’s first-in-class, novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268 for the treatment of ulcerative colitis.
Product Name : ALTB-268
Product Type : Antibody
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : Leiolizumab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : BVF Partners
Deal Size : $225.0 million
Deal Type : Series B Financing
Lead Product(s) : Leiolizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALTB-268 is a tetravalent PSGL-1 agonist antibody that acts as an immune checkpoint enhancer (ICE) to preferentially downregulate chronically activated T-cells by inhibiting the T-cell effector function, promoting T-cell exhaustion and apoptosis.
Product Name : ALTB-268
Product Type : Antibody
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : Leiolizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leiolizumab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALTB-268 is an antibody injection which works by targeting PSGL-1, it is currently being investigated for the treatment of an IBD disease, Ulcerative Colitis.
Product Name : ALTB-268
Product Type : Antibody
Upfront Cash : Inapplicable
July 12, 2023
Lead Product(s) : Leiolizumab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leiolizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALTB-268 is a next-generation PSGL-1 antibody agonist that acts as an immune checkpoint enhancer (ICE) that downregulates chronically activated T-cells by inhibiting the T-cell effector function, promoting T-cell exhaustion and apoptosis.
Product Name : ALTB-268
Product Type : Antibody
Upfront Cash : Inapplicable
January 23, 2023
Lead Product(s) : Leiolizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Neihulizumab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALTB-168 (neihulizumab) is an immune checkpoint enhancer that regulates T cell homeostasis. This agonist antibody maintains T cell homeostasis by downregulating of activated T cells, potentially sparing resting T cells and early-activated T cells thus co...
Product Name : ALTB-168
Product Type : Antibody
Upfront Cash : Inapplicable
January 19, 2023
Lead Product(s) : Neihulizumab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leiolizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALTB-268 is a tetravalent PSGL-1 agonist antibody that acts as an immune checkpoint enhancer (ICE) to preferentially downregulate chronically activated T-cells by inhibiting the T-cell effector function, promoting T-cell exhaustion and apoptosis.
Product Name : ALTB-268
Product Type : Antibody
Upfront Cash : Inapplicable
January 08, 2023
Lead Product(s) : Leiolizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Neihulizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALTB-168 (neihulizumab), is immune checkpoint agonist antibody that regulates T cell homeostasis, unique mechanism of action provides a natural regulation of T cell homeostasis that induces cell death.
Product Name : ALTB-168
Product Type : Antibody
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Neihulizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Neihulizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The company will share development plans for next generation immune checkpoint enhancer, ALTB-268, bearing the same mechanism of action with increased potency for subcutaneous administration in ulcerative colitis patients.
Product Name : ALTB-168
Product Type : Antibody
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : Neihulizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Leiolizumab
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALTB-268 is a next-generation PSGL-1 antibody agonist that acts as an immune checkpoint enhancer (ICE) that downregulate chronically activated T-cells by inhibiting the T-cell effector function, promoting T-cell exhaustion and apoptosis.
Product Name : ALTB-268
Product Type : Antibody
Upfront Cash : Inapplicable
June 12, 2022
Lead Product(s) : Leiolizumab
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Neihulizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Neihulizumab (ALTB-168) is an immune checkpoint enhancer that regulates T cell homeostasis, unique mechanism of action of this agonist antibody maintains T cell homeostasis by preferentially inducing downregulation of activated T cells.
Product Name : ALTB-168
Product Type : Antibody
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Neihulizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable